Transparency Market Research (TMR) has published a new report titled, ‘Therapeutic Plasma Exchange (TPE) Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global therapeutic plasma exchange (TPE) market was valued at US$ 1,063.38 Mn in 2017 and is projected to expand at a CAGR of 7.5% from 2018 to 2026. Increase in indications of plasma exchange in chronic diseases, cost advantage of plasma exchange over other therapies in certain disorders, and favorable reimbursement scenario are the factors likely to drive the global therapeutic plasma exchange market from 2018 to 2026.
Clinical applications of therapeutic plasma exchange are increasing rapidly in terms of scope and number. Plasma exchange is recommended as the first line of therapy in several chronic as well as acute diseases. Therapeutic plasma exchange is considered a promising method in some potentially fatal intoxication. In phalloid mushroom intoxication, plasma exchange was as effective as haemoperfusion in reducing mortality from as high as 30% to 50% with conventional therapy to less than 20%. Plasma exchange is highly effective in the treatment of life threatening intoxications with 4-cyclic (maprotyline) and tricyclic (amitriptyline) antidepressants. It is helpful in removing drugs such as L-thyroxine, diltiazem, verapamil, and carbamazepine from plasma. It has also been used to remove protein-bound heavy metals in plasma and phosphoroorganic intoxications.
Request A Sample-
The report offers detailed segmentation of the global therapeutic plasma exchange (TPE) market based on disease indication and end-user. In terms of disease indication, the neurological disorders segment is anticipated to account for the largest market share, as most of the indications in ASFA guidelines in category I and II are for neurological disorders.